|
norgestrel Ovrette
Pharmacologic classification: progestin Therapeutic classification: contraceptive Pregnancy risk category X
Available forms Available by prescription only Tablets: 0.075 mg
Indications and dosages
Contraception. Adults: 1 tablet P.O. daily, beginning on first day of menstruation.
Pharmacodynamics Contraceptive action: Norgestrel suppresses ovulation and causes thickening of cervical mucus.
Pharmacokinetics Absorption: Well absorbed after oral administration. Distribution: No information available. Metabolism: No information available. Excretion: No information available.
| Route |
Onset |
Peak |
Duration |
| P.O. |
Unknown |
Unknown |
Unknown |
|
Contraindications and precautions Contraindicated in pregnant women, patients hypersensitive to drug, and patients with thromboembolic disorders, cerebral
apoplexy, or history of these conditions; breast cancer; undiagnosed abnormal vaginal bleeding; severe hepatic disease; or
missed abortion. Use cautiously in patients with renal or cardiac disease, diabetes mellitus, migraine, seizures, asthma, or mental depression.
Interactions Drug-drug. Anti-infectives, carbamazepine, phenobarbital, phenytoin, rifampin: Decreases effectiveness of norethindrone. Advise patient to use alternative form of contraception. Bromocriptine: May cause amenorrhea or galactorrhea, which interferes with the action of bromocriptine. Don’t administer together. Drug-herb. St. John’s wort: Decreases effectiveness of hormonal contraceptives; causes breakthrough bleeding. Discourage use together.
Adverse reactions CNS: cerebral thrombosis or hemorrhage, migraine, depression, CVA. CV: thrombophlebitis, pulmonary embolism, edema, thromboembolism. EENT: exophthalmos, diplopia. GU: breakthrough bleeding, change in menstrual flow, dysmenorrhea, spotting, amenorrhea, cervical erosion. Hepatic: cholestatic jaundice. Metabolic: altered weight. Skin: melasma, rash, acne, pruritus. Other: breast tenderness, enlargement, or secretion.
Effects on lab test results May increase liver function test values. May increase amino acid levels. May decrease pregnanediol excretion and glucose tolerance.
Overdose and treatment No information available.
Special considerations Norgestrel is also known as the minipill. Failure rate of the progestin-only contraceptive is about three times higher than that of combination contraceptives. Ovrette tablets contain tartrazine. Use cautiously in patients with tartrazine or aspirin sensitivity. Monitor liver function test results in patients with hepatic impairment and patients receiving prolonged therapy. Breast-feeding patients If possible, advise breast-feeding women not to use hormonal contraceptives until infant is completely weaned because drug
may interfere with lactation by decreasing the quantity and quality of breast milk. Recommend other means of contraception.
Patient education Tell patient to take drug at the same time every day, even during menstruation. Advise patient of increased risk of serious CV adverse reactions linked to heavy smoking, especially while using hormonal
contraceptives. Tell patient that risk of pregnancy increases with each tablet missed. If she misses one tablet, tell her to take it as soon
as she remembers and then take the next tablet at the regular time. If she misses two tablets, tell her to take one as soon
as she remembers, take the next regular dose at the usual time, and use a nonhormonal method of contraception in addition
to norgestrel until 14 tablets have been taken. If she misses three or more tablets, tell her to discontinue drug and use
a nonhormonal method of contraception until after her menstrual period. Instruct patient to perform a pregnancy test if her
menstrual period doesn’t occur within 45 days. Advise patient to report excessive bleeding or bleeding between menstrual cycles immediately. Instruct patient to use a second method of contraception for the first cycle on norgestrel, or for 3 weeks after starting
the hormonal contraceptive, to ensure full protection. Advise patient who wishes to become pregnant to wait at least 3 months after discontinuing norgestrel, to prevent birth defects.
Reactions may be common, uncommon, life-threatening, or
COMMON AND LIFE THREATENING.
◆ Canada only
◇ Unlabeled clinical use
|